Health Discovery (HDVY) 10-Q 15 May 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2014	15-May-14
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'HEALTH DISCOVERY CORP	'
Entity Central Index Key	'0001141788	'
Trading Symbol	'hdvy	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	252,557,310
Document Type	'10-Q	'
Document Period End Date	31-Mar-14	'
Amendment Flag	'false	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'

Balance_Sheets_unaudited

Balance Sheets (unaudited) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Current Assets	'	'
Cash	$38,737	$71,991
Accounts Receivable	61	80
Investment in Available For Sale Securities (Note G)	624,600	724,000
Total Current Assets	663,398	796,071
Equipment, Less Accumulated Depreciation of $56,656 and $55,133	4,229	5,752
Other Assets	'	'
Patents, Less Accumulated Amortization of $2,584,970 and $2,519,290	1,400,824	1,466,504
Total Assets	2,068,451	2,268,327
Current Liabilities	'	'
Accounts Payable - Trade	337,715	326,267
Accrued Liabilities	5,000	2,500
Dividends Payable - S/T	326,137	308,724
Deferred Revenue	779,588	1,024,988
Total Current Liabilities	1,448,440	1,662,479
Long Term Liabilities	'	'
Deferred Revenue	180,781	191,628
Total Liabilities	1,629,221	1,854,107
Stockholders' Equity	'	'
Common Stock, No Par Value, 300,000,000 Shares Authorized 252,557,310 Shares Issued and Outstanding March 31, 2014 252,557,310 Shares Issued and Outstanding December 31, 2013	26,370,194	26,368,892
Accumulated Deficit	-26,868,866	-26,792,574
Total Stockholders' Equity	439,230	414,220
Total Liabilities and Stockholders' Equity	2,068,451	2,268,327
Series B Preferred Stock Convertible	'	'
Stockholders' Equity	'	'
Preferred Stock Convertible	677,902	677,902
Series C Preferred Stock Convertible	'	'
Stockholders' Equity	'	'
Preferred Stock Convertible	$260,000	$160,000

Balance_Sheets_unaudited_Paren

Balance Sheets (unaudited) (Parentheticals) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Accumulated depreciation on equipment (in dollars)	$56,656	$55,133
Accumulated amortization on patents (in dollars)	$2,584,970	$2,519,290
Common Stock, no par value (in dollars per share)	'	'
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	252,557,310	252,557,310
Common stock, shares outstanding	252,557,310	252,557,310
Series B Preferred Stock Convertible	'	'
Preferred stock, shares authorized	20,625,000	20,625,000
Preferred stock, shares issued	8,827,500	8,827,500
Preferred stock, shares outstanding	8,827,500	8,827,500
Series C Preferred Stock Convertible	'	'
Preferred stock, shares authorized	16,500,000	16,500,000
Preferred stock, shares issued	4,333,334	2,000,000
Preferred stock, shares outstanding	4,333,334	2,000,000

Statements_of_Operations_unaud

Statements of Operations (unaudited) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Revenues:	'	'
Licensing & Development	$261,359	$284,139
Operating Expenses:	'	'
Amortization	65,680	65,680
Professional and Consulting Fees	91,917	279,083
Legal Fees	16,681	39,155
Research & Development Fees	23,438	35,151
Compensation	78,530	166,025
Other General and Administrative Expenses	43,685	114,333
Total Operating Expenses	319,931	699,427
Loss From Operations	-58,572	-415,288
Other (Expense) Income	'	'
Unrealized (Loss) Gain on Available for Sale Securities (Note G)	-70,800	459,650
Realized Gain on Available for Sale Securities (Note G)	53,080	270,450
Total Other (Expense) Income	-17,720	730,100
Net (Loss) Income	-76,292	314,812
Preferred Stock Dividends	17,413	34,205
(Loss) Income Attributable to Common Shareholders	($93,705)	$280,607
Weighted Average Outstanding Shares	'	'
Basic (in shares)	252,557,310	233,773,144
Diluted (in shares)	252,557,310	251,141,406
(Loss) Income Per Share (basic and diluted) (in dollars per share)	$0	$0.00

Statements_of_Cash_Flows_unaud

Statements of Cash Flows (unaudited) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Cash Flows From Operating Activities	'	'
Net (Loss) Income	($76,292)	$314,812
Adjustments to Reconcile Net (Loss) Income to Net Cash Used for Operating Activities:	'	'
Stock-based Compensation	3,837	17,931
Services Exchanged for Options	14,878	10,158
Realized Gain on Investments in Available for Sale Securities Measured in Accordance with the Fair Value Option (Note G)	-53,080	-270,450
Unrealized Loss (Gain) on Investments in Available for Sale Securities Measured in Accordance with the Fair Value Option (Note G)	70,800	-459,650
Depreciation and Amortization	67,203	67,832
Decrease (Increase) in Accounts Receivable	19	-108
Decrease in Deferred Revenue	-256,247	-256,247
Increase (Decrease) in Accounts Payable - Trade	11,448	-41,482
Increase (Decrease) in Accrued Liabilities	2,500	-50,500
Net Cash Used for Operating Activities	-214,934	-667,704
Cash Flows From Investing Activity:	'	'
Proceeds from Sale of Available for Sale Securities (Note G)	81,680	581,475
Net Cash Provided by Investing Activity	81,680	581,475
Cash Flows From Financing Activity:	'	'
Proceeds from Series C Preferred Stock Issuance	100,000	'
Net Cash Provided by Financing Activity	100,000	'
Net Decrease in Cash	-33,254	-86,229
Cash, at Beginning of Period	71,991	171,424
Cash, at End of Period	$38,737	$85,195

BASIS_OF_PRESENTATION

BASIS OF PRESENTATION	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
BASIS OF PRESENTATION	'
	Note A - BASIS OF PRESENTATION
	Health Discovery Corporation (the “Company”) is a biotechnology-oriented company that has acquired patents and has patent pending applications for certain machine learning tools, primarily pattern recognition techniques using advanced mathematical algorithms to analyze large amounts of data thereby uncovering patterns that might otherwise be undetectable.  Such machine learning tools are currently in use for diagnostics and drug discovery, but are also marketed for other applications.  The Company licenses the use of its patented protected technology and may provide services to develop specific learning tools under development agreements or to sell to third parties.
	The accounting principles followed by the Company and the methods of applying these principles conform with accounting principles generally accepted in the United States of America (GAAP).  In preparing financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts in the financial statements.  Actual results could differ significantly from those estimates.
	The interim financial statements included in this report are unaudited but reflect all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial position and results of operations for the interim periods presented.  All such adjustments are of a normal recurring nature.  The results of operations for the three month period ended March 31, 2014 are not necessarily indicative of the results of a full year’s operations and should be read in conjunction with the financial statements and footnotes included in the Company’s annual report on Form 10-K for the year ended December 31, 2013.

REVENUE_RECOGNITION

REVENUE RECOGNITION	3 Months Ended
	Mar. 31, 2014
Deferred Revenue Disclosure [Abstract]	'
REVENUE RECOGNITION	'
	Note B – REVENUE RECOGNITION
	Revenue is generated through the sale or license of patented technology and processes and from services provided through development agreements.  These arrangements are generally governed by contracts that dictate responsibilities and payment terms.  The Company recognizes revenues as they are earned over the duration of a license agreement or upon the sale of any owned patent once all contractual obligations have been fulfilled.  If a license agreement has an undetermined or unlimited life, the revenue is recognized over the remaining expected life of the patents. Revenue is recognized under development agreements in the period the services are performed.
	The Company treats the incremental direct cost of revenue arrangements, which consists principally of employee bonuses, as deferred charges and these incremental direct costs are amortized to expense using the straight-line method over the same term as the related deferred revenue recognition.
	Deferred revenue represents the unearned portion of payments received in advance for licensing and development agreements.  The Company had total unearned revenue of $960,369 as of March 31, 2014.  Unearned revenue of $779,588 is recorded as current and $180,781 is classified as long-term.

NET_LOSS_INCOME_PER_SHARE

NET (LOSS) INCOME PER SHARE	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
NET (LOSS) INCOME PER SHARE	'
	Note C - NET (LOSS) INCOME PER SHARE
	Basic Earnings Per Share (“EPS”) includes no dilution and is computed by dividing income or loss available to common shareholders by the weighted average number of common shares outstanding for the period.  Diluted EPS reflects the potential dilution of securities that could share in the earnings or losses of the entity.
	For the three-month period ending March 31, 2014, both the basic and diluted per share loss are computed by dividing net loss by the weighted average number of common shares outstanding for the period. The calculation of diluted per share amounts would have created an anti-dilutive result due to the net loss for the period.
	The following is an analysis of the basic and diluted earnings per common share computations for the three months ended March 31, 2013:
		Three months ended
		31-Mar-13
	Basic:
	Net income attributable to common shareholders	$	280,607
	Basic weighted average common shares outstanding		233,773,144
	Basic earnings per common share	$	0.001
	Diluted:
	Net income attributable to common shareholders	$	314,812
	Basic weighted average common shares outstanding		233,773,144
	Effect of dilutive securities:
	Conversion of options and warrants		28,087
	Conversion of preferred shares to common shares		17,340,175
	Diluted weighted average common shares outstanding		251,141,406
	Diluted earnings per common share	$	0.001
	During the three month period ended March 31, 2013, 5,500,000 outstanding stock options and warrants were not included in the computation of diluted earnings per common share because to do so would have an antidilutive effect.
	In addition, for the three month period ended March 31, 2014, 4,750,000 outstanding stock options and warrants were not included in the computation of diluted earnings per share as doing so would have an antidilutive effect.

STOCKBASED_COMPENSATION_AND_OT

STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS	3 Months Ended
	Mar. 31, 2014
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]	'
STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS	'
	Note D - STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS
	Stock-based expense included in our net income for the three months ended March 31, 2014 consisted of $18,715 for stock options granted to directors, officers and advisors.  Stock-based expense included in our net loss for the three months ended March 31, 2013 was $28,089.
	As of March 31, 2014, there was $175,225 of unrecognized cost related to stock option and warrant grants.  The cost is to be recognized over the remaining vesting periods that average approximately 2.5 years.
	There were no grants, exercises, forfeitures, or expirations of stock options and warrants for the three months ended March 31, 2014.  As of March 31, 2014, there were 13,500,000 option and warrant shares outstanding with a weighted average exercise price of $0.05.
	The following schedule summarizes combined stock option and warrant information as of March 31, 2014:
	Exercise Prices	Number	Weighted-	Number	Weighted
		Outstanding	Average	Exercisable	Average
			Remaining		Remaining
			Contractual		Contractual Life
			Life (years)		(years) of
					Exercisable
					Warrants and
					Options
	$0.03	3,000,000	9.25	-	-
	$0.04	7,750,000	9.5	2,000,000	9.5
	$0.04	1,000,000	3.75	1,000,000	3.75
	$0.05	1,000,000	3.75	1,000,000	3.75
	$0.08	750,000	0.25	750,000	.25
	Total	13,500,000		4,750,000
	The weighted average remaining life of all outstanding warrants and options at March 31, 2014 is 8 years.  As of March 31, 2014, the aggregate net intrinsic value of all options and warrants outstanding is $12,000, based on the market closing price of $0.031 on March 31, 2014 less exercise prices.

PATENTS

PATENTS	3 Months Ended
	Mar. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
PATENTS	'
	Note E - PATENTS
	The Company has acquired and developed a group of patents related to biotechnology and certain machine learning tools used for diagnostic and drug discovery. Legal costs associated with patent acquisitions and the application processes for new patents are also capitalized as patent assets. The Company has recorded as other assets $1,400,824 in patents and patent related costs, net of $2,584,970 in accumulated amortization, at March 31, 2014.
	Amortization charged to operations for the three months ended March 31, 2014 and 2013 was $65,680 in both years. Estimated amortization expense is $262,720 for calendar year 2014 through 2018, and $152,904 in 2019.

STOCKHOLDERS_EQUITY

STOCKHOLDERS' EQUITY	3 Months Ended
	Mar. 31, 2014
Stockholders Equity Note [Abstract]	'
STOCKHOLDERS' EQUITY	'
	Note F – STOCKHOLDERS’ EQUITY
	Series B Preferred Stock
	The Company sold to individual investors a total of 19,402,675 shares of Series B Preferred Stock for $1,490,015, net of associated expenses, in 2009.
	The Series B Preferred Stock may be converted into Common Stock of the Company at the option of the holder, without the payment of additional consideration by the holder, so long as the Company has a sufficient number of authorized shares to allow for the exercise of all of its outstanding warrants and options. The shares of Series B Preferred Stock will convert into Common Stock of the Company in the fourth quarter of 2014, which is the fifth anniversary of the date of issuance.
	The Series B Preferred Stock has accrued dividends at the rate of 10% of the Series B Original Issue Price per year, which shall be satisfied by the fifth anniversary of the issuance of such shares of the Series B Preferred Stock (the “Original Issue Date”) by the Company’s issuance of the number of shares of Common Stock equal to such accrued dividends divided by the average closing price of the Company’s Common Stock as reported on the Over-the-Counter-Bulletin Board or other exchange on which the Company’s Common Stock trades during the prior ten business days or by the payment of cash, as the Company may determine in its sole discretion. Dividends have been accrued for the Series B Preferred Stock in the amount of $326,137 as of March 31, 2014 and $308,724 as of December 31, 2013. The Company plans to satisfy the accrued dividend for the Series B Preferred Stock in the fourth quarter of 2014.
	Subject to the limitations set forth in the Amended and Restated Articles of Amendment to Articles of Incorporation and applicable law, as long as the Series B Preferred Stock remain outstanding, the Company is required to pay the holders of the Series B Preferred Stock a special dividend equal to 15% of Company Net Revenue collected beginning with the Original Issue Date and ending on the date the Series B Preferred Stock cease to be outstanding (the “Cash Bonus”).  Company Net Revenue include, but is not limited to, revenue derived from development fees, license fees and royalties paid to the Company and revenue collected as a result of the sale of any asset of the Company or distributions from SVM Capital, LLC (each a “Revenue Contract”), reduced by the amount of any out-of-pocket costs or expenses that are directly related to obtaining, negotiating or documenting the Revenue Contracts and the performance of such Revenue Contracts, but does not include the proceeds of any capital infusions from the exercise of outstanding options or warrants or as a result of any capital raise undertaken by the Company.  At any time following the Original Issue Date, the Company may satisfy the special dividend right in its entirety if the aggregate payments made to the Series B Holders are equal to that value which provides an internal annual rate of return of twenty percent (20%) on the Series B Preferred Stock.  The maximum Cash Bonus to be paid each year shall be the aggregate Series B Original Issue Price, and no amounts in excess of such amount shall accrue or carry-over to subsequent years. No special dividends are accrued for the Series B Preferred Stock special dividend as of March 31, 2014 and December 31, 2013.
	No dividend payment will be made if, after the payment of such dividend, the Company would not be able to pay its debts as they become due in the usual course of business, or the Company’s total assets would be less than the sum of its total liabilities plus the amount that would be needed, if the Company were to be dissolved, to satisfy the preferential rights upon the dissolution to shareholders whose preferential rights are superior to those receiving the dividend.
	Series C Preferred Stock
	In the fourth quarter of 2013, the Board of Directors authorized issuing up to 12,500,000 Series C Preferred Shares and the Company began to receive funding for the Series C Preferred Shares. As of December 31, 2013 2,000,000 shares were issued at $0.08 for a total of $160,000. During the first quarter of 2014, the Company lowered the price of the Series C Preferred Shares to $0.06, raised the authorized amount to 16,500,000 shares, and issued an additional 666,667 shares to the Subscribers who bought shares in 2013 at $0.08 per share. As of March 31, 2014 the Company had outstanding 4,333,334 preferred shares at $0.06 for a total of $260,000. The Series C Preferred Shares feature $0.08 warrants and $0.08 contingency warrants. The contingency warrants will be issued only if the company has not attained profitability by the end of the first quarter 2016. The holders must exercise fifty percent of the warrants if the market price for the Company’s common stock is $0.20 for a period of thirty consecutive calendar days.  The holders must also exercise fifty percent of the warrants if the market price for the Company’s common stock is $0.30 for a period of thirty consecutive calendar days.  The warrants were valued at $0.025 each using the Black Scholes Method.
	The goal is to raise a maximum of $1,000,000 funds via this funding. This funding is anti-dilutive because the purchase price is significantly higher than the current 180-day average share price. The Series C Preferred Stock has not been registered under either federal or state securities laws and must be held until a registration statement covering such securities is declared effective by the Securities and Exchange Commission or an applicable exemption applies.
	The Series C Preferred Stock may be converted into Common Stock of the Company at the option of the holder, without the payment of additional consideration by the holder, so long as the Company has a sufficient number of authorized shares to allow for the exercise of all of its outstanding warrants and options. The Shares of Series C Preferred Stock must be converted into Common Stock of the Company either by the demand by the shareholder or at the fifth anniversary of the date of issuance.

INVESTMENT_IN_AVAILABLE_FOR_SA

INVESTMENT IN AVAILABLE FOR SALE SECURITIES	3 Months Ended
	Mar. 31, 2014
Available-For-Sale Securities [Abstract]	'
INVESTMENT IN AVAILABLE FOR SALE SECURITIES	'
	Note G – INVESTMENT IN AVAILABLE FOR SALE SECURITIES
	The Company has elected the fair value option in accordance with ASC 825, Financial Instruments, as it relates to its shares held in NeoGenomics’ common stock that were acquired resulting from the NeoGenomics Master License Agreement executed on January 6, 2012. Management made the election for the fair value option related to this investment because it believes the fair value option for the NeoGenomics common stock provides a better measurement from which to compare financial statements from reporting period to reporting period. No other financial assets or liabilities are measured at fair value using the fair value option.
	The Company’s investment in NeoGenomics’ common stock is recorded on the accompanying balance sheets under the caption Investment in Available for Sale Securities. The carrying value of this investment on the date of acquisition approximated $1,945,000. The change in fair value from December 31, 2013 to March 31, 2014 was a net loss of $17,720 for the remaining 180,000 shares held and is classified as other expense under the captions Realized and Unrealized (Loss) Gain on Available for Sale Securities in the accompanying statements of operations. The change in fair value from December 31, 2012 to March 31, 2013 was $730,100 and is classified as other income under the captions Realized and Unrealized Gain on Available for Sale Securities for the three months ended March 31, 2013 in the accompanying statements of operations. The Company classifies its investment as an available for sale security presented as a trading security on the balance sheet and the fair value is considered a Level 1 investment in the fair value hierarchy. The March 31, 2014 fair value of the investment of $624,600 is for the remaining shares held and is calculated using the closing stock price of the NeoGenomics common stock at the end of the reporting period.
	As of March 31, 2014 the Company held 180,000 shares of NeoGenomics stock as compared to 200,000 shares as of December 31, 2013.  The initial 1,360,000 shares were acquired in January 2012 as a result of the NeoGenomics Master License Agreement.

COMMITMENTS

COMMITMENTS	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
COMMITMENTS	'
	Note H – COMMITMENTS
	From time to time, the Company is subject to various claims primarily arising in the normal course of business. Although the outcome of these matters cannot be determined, the Company does not believe it is probable that any such claims will result in material costs and expenses.

NET_LOSS_INCOME_PER_SHARE_Tabl

NET (LOSS) INCOME PER SHARE (Tables)	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Schedule of analysis of the basic and diluted earnings per common share computations	'
		Three months ended
		31-Mar-13
	Basic:
	Net income attributable to common shareholders	$	280,607
	Basic weighted average common shares outstanding		233,773,144
	Basic earnings per common share	$	0.001
	Diluted:
	Net income attributable to common shareholders	$	314,812
	Basic weighted average common shares outstanding		233,773,144
	Effect of dilutive securities:
	Conversion of options and warrants		28,087
	Conversion of preferred shares to common shares		17,340,175
	Diluted weighted average common shares outstanding		251,141,406
	Diluted earnings per common share	$	0.001

STOCKBASED_COMPENSATION_AND_OT1

STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS (Tables)	3 Months Ended
	Mar. 31, 2014
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]	'
Schedule of combined stock option and warrant information of the company	'
	Exercise Prices	Number	Weighted-	Number	Weighted
		Outstanding	Average	Exercisable	Average
			Remaining		Remaining
			Contractual		Contractual Life
			Life (years)		(years) of
					Exercisable
					Warrants and
					Options
	$0.03	3,000,000	9.25	-	-
	$0.04	7,750,000	9.5	2,000,000	9.5
	$0.04	1,000,000	3.75	1,000,000	3.75
	$0.05	1,000,000	3.75	1,000,000	3.75
	$0.08	750,000	0.25	750,000	.25
	Total	13,500,000		4,750,000

REVENUE_RECOGNITION_Detail_Tex

REVENUE RECOGNITION (Detail Textuals) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Deferred Revenue Disclosure [Abstract]	'	'
Total unearned revenue	$960,369	'
Current unearned revenue	779,588	1,024,988
Unearned revenue long term	$180,781	$191,628

NET_INCOME_LOSS_PER_SHARE_Summ

NET INCOME (LOSS) PER SHARE - Summary of basic and diluted earnings per common share computations (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Basic:	'	'
Net income attributable to common shareholders	($93,705)	$280,607
Basic weighted average common shares outstanding	252,557,310	233,773,144
Basic earnings per common share	'	$0.00
Diluted:	'	'
Net income attributable to common shareholders	'	$314,812
Basic weighted average common shares outstanding	252,557,310	233,773,144
Effect of dilutive securities:	'	'
Conversion of options and warrants	'	28,087
Conversion of preferred shares to common shares	'	17,340,175
Diluted weighted average common shares outstanding	252,557,310	251,141,406
Diluted earnings per common share	'	$0.00

NET_LOSS_INCOME_PER_SHARE_Deta

NET (LOSS) INCOME PER SHARE (Detail Textuals) (Stock Options and Warrants)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Stock Options and Warrants	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive securities not included in the computation of diluted earnings per common share	4,750,000	5,500,000

STOCKBASED_COMPENSATION_AND_OT2

STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS (Details) (Stock Options and Warrants, USD $)	3 Months Ended
	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Exercise Prices	$0.05
Number Outstanding	13,500,000
Weighted-Average Remaining Contractual Life (years)	'8 years
Number Exercisable	4,750,000
Exercise Price $0.027	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Exercise Prices	$0.03
Number Outstanding	3,000,000
Weighted-Average Remaining Contractual Life (years)	'9 years 3 months
Number Exercisable	'
Exercise Price $0.036	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Exercise Prices	$0.04
Number Outstanding	7,750,000
Weighted-Average Remaining Contractual Life (years)	'9 years 6 months
Number Exercisable	2,000,000
Weighted Average Remaining Contractual Life (years) of Exercisable Warrants and Options	'9 years 6 months
Exercise Price $0.040	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Exercise Prices	$0.04
Number Outstanding	1,000,000
Weighted-Average Remaining Contractual Life (years)	'3 years 9 months
Number Exercisable	1,000,000
Weighted Average Remaining Contractual Life (years) of Exercisable Warrants and Options	'3 years 9 months
Exercise Price $0.050	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Exercise Prices	$0.05
Number Outstanding	1,000,000
Weighted-Average Remaining Contractual Life (years)	'3 years 9 months
Number Exercisable	1,000,000
Weighted Average Remaining Contractual Life (years) of Exercisable Warrants and Options	'3 years 9 months
Exercise Price $0.080	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Exercise Prices	$0.08
Number Outstanding	750,000
Weighted-Average Remaining Contractual Life (years)	'3 months
Number Exercisable	750,000
Weighted Average Remaining Contractual Life (years) of Exercisable Warrants and Options	'3 months

STOCKBASED_COMPENSATION_AND_OT3

STOCK-BASED COMPENSATION AND OTHER EQUITY BASED PAYMENTS (Detail Textuals) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock-based compensation	$18,715	$28,089
Stock Options and Warrants	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Total compensation unrecognized for stock options and warrants	175,225	'
Average remaining vesting period for recognition of unrecognized expenses related to stock options and warrants	'2 years 6 months	'
Number outstanding	13,500,000	'
Weighted average exercise price	$0.05	'
Weighted average remaining life of outstanding warrants and options	'8 years	'
Aggregate net intrinsic value of options and warrants outstanding	$12,000	'
Market closing price less exercise prices	$0.03	'

PATENTS_Detail_Textuals

PATENTS (Detail Textuals) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'	'	'
Patents and patent related costs, net	$1,400,824	'	$1,466,504
Accumulated amortization of patents	2,584,970	'	2,519,290
Amortization charged on patents	65,680	65,680	'
Estimated amortization expense of patents at 2014	262,720	'	'
Estimated amortization expense of patents at 2015	262,720	'	'
Estimated amortization expense of patents at 2016	262,720	'	'
Estimated amortization expense of patents at 2017	262,720	'	'
Estimated amortization expense of patents at 2018	262,720	'	'
Estimated amortization expense of patents at 2019	$152,904	'	'

STOCKHOLDERS_EQUITY_Detail_Tex

STOCKHOLDERS' EQUITY (Detail Textuals) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Dec. 31, 2009
			Series B Preferred Stock	Series B Preferred Stock
Class of Stock [Line Items]	'	'	'	'
Number of preferred stock issued (in shares)	'	'	'	19,402,675
Amount of preferred stock issued	'	'	'	$1,490,015
Dividend rate on preferred stock	'	'	10.00%	'
Dividend accrued on Series B preferred stock	$326,137	$308,724	'	'
Percentage of special dividend for preferred stock	'	'	15.00%	'
Internal annual rate of return on preferred stock	'	'	20.00%	'

STOCKHOLDERS_EQUITY_Detail_Tex1

STOCKHOLDERS' EQUITY (Detail Textuals 1) (Series C Preferred Stock, USD $)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Series C Preferred Stock	'	'
Class Of Stock [Line Items]	'	'
Number of shares authorized to be issued	'	12,500,000
Preferred stock, shares issued	4,333,334	2,000,000
Preferred stock, shares outstanding	4,333,334	2,000,000
Preferred stock, shares authorized	16,500,000	16,500,000
Par value of preferred shares issued	$0.06	$0.08
Value of preferred shares issued	$260,000	$160,000
Additional shares issued to subscribers	666,667	'
Preferred shares warrant feature per share	$0.08	'
Preferred shares contingency warrant feature per share	$0.08	'
Series C Preferred stock, contingency warrant exercise description	'The contingency warrants will be issued only if the company has not attained profitability by the end of the first quarter 2016. The holders must exercise fifty percent of the warrants if the market price for the Company's common stock is $0.20 for a period of thirty consecutive calendar days.	'
Percentage of warrants exercise if market price for Company's common stock is $0.20	50.00%	'
Price per share for exercise of warrants, condition one	0.2	'
Number of days for common stock price at $0.20	'30 days	'
Percentage of warrants exercise if market price for Company's common stock is $0.30	50.00%	'
Price per share for exercise of warrants, condition two	0.3	'
Number of days for common stock price at $0.30	'30 days	'
Valuation method for warrants	'Black Scholes Method	'
Fair value of exercise price of warrants	$0.03	'
Maximum amount of fund raising	$1,000,000	'

INVESTMENT_IN_AVAILABLE_FOR_SA1

INVESTMENT IN AVAILABLE FOR SALE SECURITIES (Detail Textuals) (Neo Genomics Laboratories Inc, USD $)	3 Months Ended	12 Months Ended	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2014
			Other income	Carrying value	Fair value
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'	'
Available for sale securities	'	'	'	$1,945,000	$624,600
Unrecognized loss on available for sale securities	17,720	'	'	'	'
Number of remaining shares held	180,000	'	'	'	'
Realized and unrealized gain on available for sale securities	'	'	$730,100	'	'
Number of shares of Neo Genomics stock held	180,000	200,000	'	'	'
Number of shares initially acquired	1,360,000	'	'	'	'